Patents Assigned to Akagera Medicines, Inc.
-
Publication number: 20230381303Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.Type: ApplicationFiled: May 25, 2023Publication date: November 30, 2023Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
-
Publication number: 20230348447Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.Type: ApplicationFiled: December 13, 2022Publication date: November 2, 2023Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin
-
Publication number: 20230219941Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.Type: ApplicationFiled: June 18, 2021Publication date: July 13, 2023Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin
-
Publication number: 20230126415Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.Type: ApplicationFiled: December 1, 2022Publication date: April 27, 2023Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin
-
Publication number: 20230126953Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.Type: ApplicationFiled: December 12, 2022Publication date: April 27, 2023Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
-
Patent number: 11591544Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.Type: GrantFiled: November 24, 2021Date of Patent: February 28, 2023Assignee: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
-
Patent number: 11566023Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.Type: GrantFiled: May 6, 2022Date of Patent: January 31, 2023Assignee: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin
-
Patent number: 11555033Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.Type: GrantFiled: June 18, 2021Date of Patent: January 17, 2023Assignee: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin
-
Publication number: 20220411394Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.Type: ApplicationFiled: August 8, 2022Publication date: December 29, 2022Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
-
Publication number: 20220274975Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.Type: ApplicationFiled: May 6, 2022Publication date: September 1, 2022Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin